DOI: 10.1111/jdv.

14252 JEADV

ORIGINAL ARTICLE

The effect of bodyweight on the efficacy and safety of

ixekizumab: results from an integrated database of three
randomised, controlled Phase 3 studies of patients with
moderate-to-severe plaque psoriasis
K. Reich,1,* L. Puig,2 L. Mallbris,3 L. Zhang,3 O. Osuntokun,3 C. Leonardi4
1
Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany
2
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
3
Eli Lilly and Company, Indianapolis, IN, USA
4
St. Louis University School of Medicine, St. Louis, MO, USA
*Correspondence: K. Reich. E-mail: kreich@dermatologikum.de

Abstract
Background There is concern that increased bodyweight may impact efficacy of some therapies used to treat psoria-
sis.
Objective To evaluate the effect of bodyweight on response to ixekizumab treatment in patients with moderate-to-
severe psoriasis.
Methods Patients were characterized under three bodyweight categories (<80 kg, 80 to <100 kg, ≥100 kg) in this pre-
planned subgroup analysis from an integrated database of three multicenter, randomised, double-blind, controlled
Phase 3 clinical studies (UNCOVER-1, UNCOVER-2 and UNCOVER-3). In the first 12 weeks of each study, patients were
randomly assigned to receive subcutaneous placebo, 80-mg ixekizumab every 2 weeks (IXE Q2W) or every 4 weeks (IXE
Q4W) after a starting dose of 160-mg ixekizumab, or 50-mg etanercept twice weekly (UNCOVER-2 and UNCOVER-3
only).
Results This analysis included 3855 patients with baseline bodyweight in the IXE Q4W (N = 1159), IXE Q2W
(N = 1168), placebo (N = 789) and etanercept (N = 739) groups. Distribution of patients across bodyweight categories
was similar between treatment groups. Baseline demographics and patients characteristics were generally consistent
across treatment groups within each bodyweight category. Across all bodyweight categories, a significantly higher
percentage of patients treated with IXE Q2W or IXE Q4W than with placebo or etanercept achieved PASI 75, PASI 90 or
PASI 100 at Week 12. No meaningful differences in PASI 75 response rates were observed across bodyweight cate-
gories. Some numerical differences in PASI 90 and PASI 100 response rates were observed between bodyweight cate-
gories with IXE Q2W providing numerically higher response rates than IXE Q4W. The incidence of treatment-emergent
adverse events was similar in the treatment groups and across bodyweight categories.
Conclusion Ixekizumab was efficacious in the treatment of moderate-to-severe psoriasis regardless of bodyweight.
The safety profile of ixekizumab was also similar across bodyweight categories, and no safety signals were identified
specific to any of the bodyweight categories.
Received: 21 December 2016; Accepted: 14 February 2017

Conflicts of interest
Prof. Reich has participated on an advisory board (honoraria) for Abbvie, Amgen, Biogen, Boehringer Ingelheim
Pharma, Celgene, Forward Pharma, Janssen-Cilag, Leo, Eli Lilly and Company, Novartis, Pfizer, Regeneron,
Takeda, UCB Pharma, and Xenoport. He has also participated as a speaker/faculty education (honoraria) for
Abbvie, Celgene, Covagen, Janssen-Cilag, Leo, Eli Lilly and Company, Medac, Merck Sharp & Dohme Corp.,
and Novartis, has participated as an author (no compensation) for Abbvie, Biogen, Celgene, Forward Pharma,
GlaxoSmithKline, Janssen-Cilag, Leo, Eli Lilly and Company, Medac, Novartis, UCB Pharma, and has
participated as a consultant (honoraria) for Abbvie, Boehringer Ingelheim Pharma, Covagen, Forward Pharma,
Janssen-Cilag, Leo, Eli Lilly and Company, UCB Pharma, and Xenoport.
Prof. Reich has received funding for research/clinical studies (paid study fees to SCIderm GmbH) from Abbvie,
Amgen, Biogen, Boehringer Ingelheim Pharma, Celgene, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Leo,

JEADV 2017, 31, 1196–1207 © 2017 European Academy of Dermatology and Venereology
Effect of bodyweight on ixekizumab treatment 1197

Eli Lilly and Company, Medac, Merck Sharp & Dohme Corp., Novartis, Regeneron, Takeda, and UCB Pharma. Dr.
Puig has received grants/research supports (clinical trials) from Abbvie, Amgen, Janssen, Eli Lilly and Company,
Novartis, Pfizer, Regeneron, and Roche, has received honoraria or consultation fees from Abbvie, Almirall,
Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Eli Lilly and Company,
Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, and Sandoz, and has participated in a company
sponsored speaker's bureau for Celgene, Janssen, Eli Lilly and Company, MSD, Novartis, and Pfizer.
Dr. Mallbris, Dr. Zhang, and Dr. Osuntokun are employees and stockholders of Eli Lilly and Company.
Dr. Leonardi is a Consultant/Advisory Board Member for Abbvie, Amgen, Boehringer-Ingelheim, Dermira, Eli Lilly
and Company, Janssen, Leo Pharmaceuticals, Pfizer, Sandoz, UCB and Vitae. He has been an investigator for
Actavis, Abbvie, Amgen, Boehringer-Ingelheim, Celgene, Coherus, Cellceutix, Corrona, Dermira, Eli Lilly and
Company, Galderma, Glenmark, Janssen, Leo Pharma, Merck, Novartis, Novella, Pfizer, Sandoz, Stiefel, Wyeth
and is on the speaker bureau for Abbvie, Celgene, Novartis and Eli Lilly and Company.

Funding sources
Funding for this research was provided by Eli Lilly and Company.

Clinicaltrials.gov
NCT01474512 (UNCOVER-1); NCT01597245 (UNCOVER-2); NCT01646177 (UNCOVER-3).

Introduction first 12 weeks of the UNCOVER studies, patients were ran-

Psoriasis is a chronic, inflammatory skin disease that affects ~3%
of the general population.1 Individuals with psoriasis are more
likely to be overweight or obese than those without psoriasis.2 In
clinical practice, patients with higher bodyweight show
decreased response to standard doses of biologic therapies that
are not weight adjusted, leading to a growing concern that
increased bodyweight may impact the efficacy of some therapies
commonly used to treat psoriasis.3
Ixekizumab is a high-affinity monoclonal antibody that selec-
tively targets interleukin-17A (IL-17A), the proinflammatory
and primary effector cytokine of type 17 helper T (Th17) cells.4
Recently, three Phase 3, randomised, double-blind, placebo-con-
trolled studies have demonstrated the efficacy and safety of ixek-
izumab in the treatment of moderate-to-severe plaque
psoriasis.5,6
The objective of this research was to evaluate the efficacy and
safety of ixekizumab versus placebo or etanercept by different
bodyweight categories (<80 kg, 80 to <100 kg, ≥100 kg) in
patients with moderate-to-severe plaque psoriasis from an inte-
grated database of three randomised controlled Phase 3 clinical
studies.
Materials and methods
Study design
UNCOVER-1, UNCOVER-2 and UNCOVER-3 were Phase 3
multicenter, randomised, double-blind, double-dummy stud-
ies that evaluated the efficacy and safety of ixekizumab in
patients with moderate-to-severe plaque psoriasis.4,5 In the
domly assigned by interactive voice response system (IVRS)
to receive subcutaneous injections of placebo (PBO), 80-mg
ixekizumab every 2 weeks (IXE Q2W) or every 4 weeks (IXE
Q4W) after a starting dose of 160-mg ixekizumab or 50-mg
etanercept twice weekly (ETN; active control in UNCOVER-
2 and UNCOVER-3 only). During each study, PBO was
given to match all active treatment regimens to maintain the
blind. For this research, analyses were restricted to the 12-
week treatment period due to differences in subsequent study
periods.
Patients
The eligibility criteria were similar in each study and are
described elsewhere.4,5 Briefly, patients were ≥18 years of age
with psoriasis that had been diagnosed ≥6 months before rando-
misation, who were candidates for phototherapy and/or systemic
therapy, with ≥10% body surface area (BSA), a static physician’s
global assessment (sPGA) score ≥3 (0–5 scale, higher scores indi-
cate more severity) and a Psoriasis Area and Severity Index
(PASI) score ≥12 (0–72 scale, higher scores indicate more sever-
ity), at both screening and baseline.
Patients with phenotypes other than plaque psoriasis, or
unstable psoriasis defined by the investigator as a recent signifi-
cant flare, were excluded. Use of medications that might con-
found efficacy was not allowed. Patients who had used ETN at
any time before screening were excluded (UNCOVER-2 and
UNCOVER-3 only). All patients gave informed written consent
for each study, and the individual study protocols received ethi-
cal review board approval.

JEADV 2017, 31, 1196–1207 © 2017 European Academy of Dermatology and Venereology
1198 Reich et al.

Assessments Statistical analyses

Overall clinical response was evaluated by the proportion of
patients with reduction from baseline PASI of at least 75% (PASI
75), at least 90% (PASI 90) and 100% (PASI 100) at Week 12 as
well as the proportion of patients achieving an sPGA score of 0
(clear) or a score of 0 (clear) or 1 (minimal) at Week 12.
Safety was evaluated by the incidence of treatment-emergent
adverse events (TEAEs), serious adverse events (SAEs) and dis-
continuations due to adverse events (AEs) reported during the
12-week treatment period. AEs of special interest included infec-
tions, injection-site reactions, candidiasis and neutropenia.
Statistical analyses of the PBO and ixekizumab groups utilized effi-
cacy and safety data from an integrated database of the three Phase
3, controlled trials (UNCOVER-1, UNCOVER-2 and UNCOVER-
3). Data for the active control (ETN) were from an integrated data-
base of UNCOVER-2 and UNCOVER-3 data only. Patients were
categorized by bodyweight into one of three groups (<80 kg; 80 to
<100 kg; ≥100 kg), which was prespecified according to regulatory
feedback. The efficacy analyses were conducted on the randomised
patients who had bodyweight recorded at baseline. Efficacy analy-
ses of this population were also conducted across the following

Figure 1 Disposition of patients with moderate-to-severe plaque psoriasis enrolled in Phase 3 ixekizumab trials. Patients were randomly
assigned to one of four treatment groups: PBO, ETN, IXE Q4W or IXE Q2W. Disposition is shown by bodyweight category (<80 kg, 80 to
<100 kg, ≥100 kg) within each treatment group. ETN, etanercept; IXE Q4W, 80-mg ixekizumab every 4 weeks; IXE Q2W, 80-mg ixek-
izumab every 2 weeks; PBO, placebo.

JEADV 2017, 31, 1196–1207 © 2017 European Academy of Dermatology and Venereology
 Table 1 Baseline demographics and clinical characteristics
PBO ETN IXE Q4W IXE Q2W
N = 789 N = 739 N = 1159 N = 1168
<80 kg 80 to <100 kg ≥100 kg <80 kg 80 to <100 kg ≥100 kg <80 kg 80 to <100 kg ≥100 kg <80 kg 80 to <100 kg ≥100 kg
Bodyweight, n (%) 258 (33%) 280 (35%) 251 (32%) 234 (32%) 254 (34%) 251 (34%) 354 (31%) 437 (38%) 368 (32%) 394 (34%) 425 (36%) 349 (30%)
Age, years 45  14 47  13 46  12 44  15 47  13 46  12 44  14 46  13 46  12 44  14 46  13 46  12
Age, range 18–79 18–77 19–72 17–79 18–88 19–73 18–82 18–88 18–77 17–84 19–78 19–75

JEADV 2017, 31, 1196–1207

Sex, n (%)
Male 127 (49%) 239 (85%) 191 (76%) 128 (55%) 194 (76%) 182 (73%) 172 (49%) 326 (75%)* 288 (78%) 178 (45%)** 321 (76%)* 267 (77%)
Female 131 (51%) 41 (15%) 60 (24%) 106 (45%) 60 (24%) 69 (28%) 182 (51%) 111 (25%) 80 (22%) 216 (55%) 104 (25%) 82 (24%)
BMI, kg/m2 24  3 29  3 38  6 25  3 30  4 38  7 24  3 30  3 38  7 24  3 30  3 38  7
BMI, n (%)
Underweight 10 (4%) 0 0 4 (2%) 0 0 7 (2%) 0 0 7 (2%) 0 0
Normal 144 (56%) 20 (7%) 0 133 (57%) 22 (9%) 0 211 (60%) 18 (4%) 0 223 (57%) 22 (5%) 0
Overweight 92 (36%) 153 (55%) 14 (6%) 86 (37%) 127 (50%) 11 (4%) 117 (33%) 249 (57%) 22 (6%) 142 (36%) 239 (57%) 19 (5%)
Obese 12 (5%) 103 (37%) 156 (62%) 11 (5%) 105 (41%) 150 (60%) 17 (5%) 167 (38%) 230 (63%) 21 (5%) 161 (38%) 217 (62%)
Effect of bodyweight on ixekizumab treatment

Extreme 0 4 (1%) 80 (32%) 0 0 90 (36%) 0 2 (<1%) 115 (31%) 0 3 (<1%) 113 (32%)
obese
Geographic
region, n (%)
Asia 11 (4%) 2 (<1%) 0 0 0 0 8 (2%) 3 (<1%) 1 (<1%) 7 (2%) 1 (<1%) 0
North America 110 (43%) 141 (50%) 152 (61%) 102 (44%) 127 (50%) 154 (61%) 167 (47%) 213 (49%) 221 (60%) 179 (45%) 206 (49%) 211 (61%)
Europe 123 (48%) 120 (43%) 90 (36%) 113 (48%) 111 (44%) 89 (36%) 156 (44%) 198 (45%) 133 (36%) 189 (48%) 199 (47%) 123 (35%)
Central/South 6 (2%) 6 (2%) 2 (<1%) 15 (6%) 11 (4%) 4 (2%) 14 (4%) 12 (3%) 3 (<1%) 16 (4%) 8 (2%) 5 (1%)
America
Australia 8 (3%) 11 (4%) 7 (3%) 4 (2%) 5 (2%) 4 (2%) 9 (3%) 11 (3%) 10 (3%) 3 (<1%) 11 (3%) 10 (3%)
Race, n (%)
Indigenous 1 (<1%) 2 (<1%) 1 (<1%) 0 2 (<1%) 2 (<1%)* 3 (<1%) 1 (<1%)* 2 (<1%) 1 (<1%) 2 (<1%)* 2 (<1%)
American†
Asian 21 (8%) 5 (2%) 8 (3%) 12 (5%) 7 (3%) 0 22 (6%) 15 (3%) 8 (2%) 26 (7%) 13 (3%) 3 (<1%)
Black/African 2 (<1%) 15 (5%) 9 (4%) 5 (2%) 9 (4%) 9 (4%) 10 (3%) 10 (2%) 10 (3%) 4 (1%) 4 (<1%) 10 (3%)
American
Native 1 (<1%) 0 0 0 0 2 (<1%) 0 0 3 (<1%) 2 (<1%) 0 2 (<1%)
Hawaiian/Pacific
Islander
White 233 (90%) 258 (92%) 232 (92%) 215 (92%) 234 (93%) 232 (93%) 316 (90%) 406 (93%) 344 (94%) 359 (91%) 403 (95%) 329 (94%)
Multiple races 0 0 1 (<1%) 1 (<1%) 1 (<1%) 4 (2%) 1 (<1%) 4 (<1%) 0 1 (<1%) 3 (<1%) 3 (<1%)
Hispanic/Latino 18 (7%) 21 (8%) 11 (4%) 27 (12%) 26 (10%) 25 (10%) 32 (9%) 41 (9%) 17 (5%) 39 (10%) 26 (6%) 28 (8%)
origin, n (%)
Duration of 20  12 19  12 19  12 19  13 18  12 18  12 19  12 19  12 19  12 18  12 19  12 19  12
psoriasis, years
Previous
systemic therapy
Never used 87 (34%) 110 (39%) 85 (34%) 80 (34%) 101 (40%) 112 (45%) 121 (34%) 145 (33%) 140 (38%) 133 (34%) 145 (34%) 125 (36%)
1199

© 2017 European Academy of Dermatology and Venereology

1200 Reich et al.

BMI, body mass index; ETN, etanercept; IXE Q4W, ixekizumab dosing every 4 weeks; IXE Q2W, ixekizumab dosing every 2 weeks; PASI, Psoriasis Area and Severity Index; PBO, placebo; SD, standard
PASI 75

3.6  0.6*,***
<80 kg

20.7  7.5
121 (35%)

76 (22%)

88 (25%)
≥100 kg

27 (8%)
80 to 100 kg
≥100 kg
-20 -15 -10 -5 0 5 10 15 20
Favours
IXE Q4W IXE Q2W
80 to <100 kg

PASI 90

19.8  7.8
154 (36%)

107 (25%)

3.5  0.6
45 (11%)
81 (19%)

<80 kg
80 to 100 kg
≥100 kg
-20 -15 -10 -5 0 5 10 15 20
19.8  8.3
175 (44%)

Favours
3.5  0.6
N = 1168
IXE Q2W

IXE Q4W IXE Q2W

55 (14%)

88 (22%)
31 (8%)

**P ≤ 0.05 vs. ETN using CMH test stratified by study for categorical data and analysis of variance (ANOVA) for continuous data. UNCOVER-2 and UNCOVER-3 only.
<80 kg

PASI 100
<80 kg
80 to 100 kg
≥100 kg
21.3  7.5
120 (33%)

3.7  0.6
40 (11%)
68 (19%)

84 (23%)
≥100 kg

-20 -15 -10 -5 0 5 10 15 20

Favours
IXE Q4W IXE Q2W
***P ≤ 0.05, IXE Q4W vs. IXE Q2W using CMH test stratified by study for categorical data and analysis of variance (ANOVA) for continuous data.

Risk difference IXE Q4W vs. IXE Q2W (% [95% CI])

80 to <100 kg

20.4  7.5
172 (39%)

3.5  0.6
43 (10%)
77 (18%)

99 (23%)

Figure 2 Risk difference of IXE Q4W versus IXE Q2W treatment

on PASI response rates at Week 12. CI, confidence interval; IXE
Q4W, 80-mg ixekizumab every 4 weeks; IXE Q2W, 80-mg ixek-
*P ≤ 0.05 vs. PBO using CMH test stratified by study for categorical data and analysis of variance (ANOVA) for continuous data.

izumab every 2 weeks; PASI, Psoriasis Area and Severity Index.

19.5  7.4
150 (42%)

3.5  0.6
N = 1159
IXE Q4W

53 (15%)

82 (23%)
30 (9%)
<80 kg

body mass index (BMI) categories: underweight <18.5 kg/m2; nor-

mal ≥18.5 to <25 kg/m2; overweight ≥25 to <30 kg/m2; obese ≥30
20.2  7.7
3.6  0.6
89 (36%)

29 (12%)

47 (19%)
≥100 kg

21 (8%)

to <40 kg/m2; and extreme obese ≥40 kg/m2. Treatment compar-

isons for efficacy responses were based on the Cochran–Mantel–
Haenszel (CMH) test stratified by study within each bodyweight
80 to <100 kg

category. Missing data were imputed using non-responder imputa-

20.0  7.4
110 (43%)

3.5  0.6
49 (19%)
20 (8%)
23 (9%)

tion. Therefore, early discontinuations were considered treatment

failures. Risk differences and 95% confidence intervals are
Data are number (percentage) of patients or mean  SD unless noted otherwise.

reported. In addition, treatment comparisons were evaluated by a

19.6  7.5
112 (48%)

logistic regression model with treatment and study as factors, and

3.5  0.6

American Indian from North, Central and South America and Alaska Native.
24 (10%)

55 (24%)
N = 739

18 (8%)
<80 kg

baseline bodyweight as a continuous covariate.

ETN

Safety analyses were conducted on all randomised patients

who received at least one dose of study treatment and had body-
21.1  8.6
3.7  0.7
71 (28%)

31 (12%)
64 (26%)

70 (28%)
≥100 kg

weight recorded at baseline. Patient disposition, categorical

demographic data and AEs were summarized and compared
deviation; sPGA, static Physician’s Global Assessment.

using CMH test stratified by study within each bodyweight cate-

80 to <100 kg

gory. The continuous demographic data were analysed within

20.3  8.3
3.6  0.6

each bodyweight category using analysis of variance with treat-

84 (30%)

28 (10%)
58 (21%)

68 (24%)

ment and study as independent factors.

Results
20.4  8.7
3.5  0.6
96 (37%)

33 (13%)
42 (16%)

66 (26%)
N = 789
<80 kg
PBO

Patient disposition
Table 1 Continued

There were 3866 patients with moderate-to-severe plaque

Psoriatic arthritis,

psoriasis in the integrated database of three Phase 3 ixek-

Biologic only
Non-biologic

Biologic and
non-biologic

izumab studies (intent-to-treat population). The baseline

PASI score

bodyweight was not recorded in 11 patients. Thus, 3855

only

sPGA

patients with baseline bodyweight values were included in

n (%)

these analyses. The distribution of patients by bodyweight

†

JEADV 2017, 31, 1196–1207 © 2017 European Academy of Dermatology and Venereology
Effect of bodyweight on ixekizumab treatment
category for the IXE Q4W (N = 1159), IXE Q2W
(N = 1168), PBO (N = 789) and ETN (N = 739) groups as
well as the number of completers and reasons for discontinu-
ation are shown in Fig. 1. The distribution of patients in the
different bodyweight categories as well as the overall distribu-
tion of baseline bodyweight were similar between treatment
groups. The number of completers and reasons for discontin-
uation were also consistent across treatment groups within
each bodyweight category (Table 1 and Fig. 1).
Baseline demographics and clinical characteristics
Baseline demographics and patients characteristics were gener-
ally consistent across treatment groups within each bodyweight
category with a few exceptions (Table 1). In the 80- to <100-kg
bodyweight category, there was significantly higher percentage
of women of the IXE Q4W and IXE Q2W groups than in the
PBO group as well as a significant difference in the distribution
of patients by race in the IXE Q2W group relative to PBO. In the
≥100-kg bodyweight category, there was a significantly lower
baseline sPGA score in the IXE Q2W group relative to IXE Q4W
and PBO.
Efficacy by bodyweight
At Week 12, across all bodyweight categories, the percentage of
patients achieving PASI 75, PASI 90 or PASI 100 was higher in
the IXE Q2W group than in the IXE Q4W group (Fig. 2).
Across all bodyweight categories, significantly more patients
in the IXE Q4W and IXE Q2W treatment groups achieved PASI
75 by Week 1, PASI 90 by Week 2 and PASI 100 by Week 4 rela-
tive to PBO or ETN (Fig. 3). The percentage of patients achiev-
ing PASI 75, PASI 90 or PASI 100 continued to increase over the
12 weeks of treatment regardless of bodyweight category.
Among ixekizumab-treated patients, at least 74% of patients in
each bodyweight category achieved PASI 75 at Week 12 (Fig. 3
and Table 2). While a numerically lower number of patients
achieved PASI 75, PASI 90 and PASI 100 with increasing body-
weight, both ixekizumab treatment groups demonstrated high
efficacy across all bodyweight categories relative to PBO and
ETN.
The individual percent improvement in PASI at Week 12 by
baseline bodyweight for each patient in the IXE Q2W group is
plotted in Fig. 4.
Similarly, across all bodyweight categories, the percentage
of patients achieving sPGA 0,1 at Week 12 was significantly
higher in the IXE Q4W (<80 kg: 79.4%; 80 to <100 kg:
78.7%; ≥100 kg: 67.4%) and IXE Q2W groups (<80 kg:
85.8%; 80 to <100 kg: 83.3%; ≥100 kg: 75.6%) than PBO
(<80 kg: 5.4%; 80 to <100 kg: 4.3%; ≥100 kg: 2.0%;
P < 0.001 all comparisons) and ETN (<80 kg: 47.4%; 80 to
<100 kg: 42.1%; ≥100 kg: 27.9%; P < 0.001 all comparisons).
The percentage of patients achieving sPGA 0 at Week 12
was also consistently higher across bodyweight categories in
JEADV 2017, 31, 1196–1207
1201
the IXE Q4W (<80 kg: 44.6%; 80 to <100 kg: 35.7%;
≥100 kg: 23.1%) and IXE Q2W group (<80 kg: 47.7%; 80 to
<100 kg: 42.4%; ≥100 kg: 26.9%) relative to PBO (<80 kg:
0%; 80 to <100 kg: 0.4%; ≥100 kg: 0%; P < 0.001 all com-
parisons) and ETN (<80 kg: 11.1%; 80 to <100 kg: 7.1%;
≥100 kg: 4.0%; P < 0.05 all comparisons). Regardless of
bodyweight, the percentage of patients achieving complete
skin clearance (sPGA 0) or nearly complete skin clearance
(sPGA 0,1) was higher in the IXE Q2W than the IXE Q4W
group.
Using a logistic regression model with baseline bodyweight
as a continuous covariate, significantly more patients in the
IXE Q4W and IXE Q2W treatment groups achieved PASI
75, PASI 90, PASI 100, sPGA (0,1) and sPGA (0) at Week
12 relative to PBO (P < 0.001 all comparisons) and ETN
(P < 0.001 all comparisons). The responses were higher with
IXE Q2W than with IXE Q4W (P < 0.05 all comparisons)
at Week 12.
Efficacy by body mass index
Across BMI categories, significantly more patients in the IXE
Q4W and IXE Q2W treatment groups achieved PASI 75,
PASI 90 and PASI 100 relative to PBO (Table 3). Similarly,
significantly more patients in the IXE Q4W and IXE Q2W
treatment groups achieved PASI 75, PASI 90 and PASI 100
relative to ETN across BMI categories except the lower
weight category. Across all BMI categories, the percentage of
patients achieving sPGA 0,1 or sPGA 0 at Week 12 was also
significantly higher in the IXE Q4W and IXE Q2W groups
than PBO (Table 3). Significantly more patients in the IXE
Q4W and IXE Q2W treatment groups achieved sPGA 0,1 or
sPGA 0 relative to ETN across BMI categories except the
lower weight category. Similar to analyses by bodyweight cat-
egories, the responses by BMI categories were generally higher
with IXE Q2W than with IXE Q4W.
Safety
In general, TEAEs, SAEs and AEs of special interest occurred at a
similar frequency for each treatment group (Table 4).
Overall, the incidence of TEAEs was significantly higher in the
IXE Q4W, IXE Q2W and ETN groups than in the PBO group
(Table 4). The most frequently reported events (occurring in
≥5% of ixekizumab-treated patients per bodyweight category)
were nasopharyngitis, upper respiratory tract infection and
injection-site reactions. Injection-site reaction was the only
TEAE that occurred at a statistically higher incidence in the
active treatment groups (IXE Q4W, IXE Q2W and ETN) than in
the PBO group. The percentage of patients who discontinued
due to AE was similar across bodyweight categories for all four
groups (range: 0.4–2.8%).
No deaths were reported during the 12-week treatment period
(Table 4). Across all bodyweight categories, SAEs occurred at a
© 2017 European Academy of Dermatology and Venereology
1202 Reich et al.

(a) <80 kg 80 kg to <100 kg ≥100 kg

PBO N = 258 PBO N = 280 PBO N = 251
ETN N = 234 ETN N = 254 ETN N = 251
Q2W N = 394 Q2W N = 437 Q2W N = 349
100 †† 100 †† 100 ††
PASI 75 †† ** †† ** **
**
** ††
80 80 80

Patients, %
†† **
**
††
60 60 ** 60 ††
**
40 †† 40 ††
40
**
** ††
20 † 20 † 20 †
**
** ** *
0 0 0
1 2 4 8 12 1 2 4 8 12 1 2 4 8 12
PASI 90 100 100 100
††
** ††
80 80 80
Patients, %

†† **
**
††
†† **
60 60 ** 60 ††
**
40 †† 40 40
** ††
** ††
20 †† 20 † 20 †
**
** **
*
0 0 0
1 2 4 8 12 1 2 4 8 12 1 2 4 8 12

PASI 100 100 100 100

80 80 80
Patients, %

60 ††
*
60 ††
60
††
*
40 * 40 40 ††
*
†† ††
††
20 *
20 †† * 20 † *
† *
*
**
0 0 0
1 2 4 8 12 1 2 4 8 12 1 2 4 8 12
Weeks Weeks Weeks

(b) <80 kg 80 kg to <100 kg ≥100 kg

Q2W N = 394 Q2W N = 425 Q2W N = 349

Q4W N = 354 # Q4W N = 437 Q4W N = 368
†† †† ##
PASI 75 100 †† ** 100 †† ** 100 ††
** ** **
††
80 80 80
Patients, %

†† **
** ††
60 60 ** 60 ††
**
†
40 **
40 †† 40
††
** **
†
20 20 † 20 †
** ** *
0 0 0
1 2 4 8 12 1 2 4 8 12 0 2 4 6 8 10 12

PASI 90 100 100 100

††
†† ** ††
Patients, %

80 80 ** 80 ††
** †† **
60 60 ** 60 ††
†† **
40 ** 40 †† 40
** ††
20 †† 20 †† 20 **
** †
** *
0 0 0
1 2 4 8 12 1 2 4 8 12 1 2 4 8 12

PASI 100 100 100 100

Patients, %

80 80 80
††
60 **
60 ††
60
†† **
40 ** 40 †† 40 ††
**
†† ** ††
20 **
20 †† 20 †
**
**
* **
0 0 0
1 2 4 8 12 1 2 4 8 12 1 2 4 8 12
Weeks Weeks Weeks

JEADV 2017, 31, 1196–1207 © 2017 European Academy of Dermatology and Venereology
Effect of bodyweight on ixekizumab treatment 1203

CI, confidence interval; ETN, etanercept; IXE Q4W, ixekizumab dosing every 4 weeks; IXE Q2W, ixekizumab dosing every 2 weeks; PASI, Psoriasis Area and Severity Index; PBO, placebo, sPGA, static
Figure 3 (a) PASI 75, PASI 90 and PASI 100 response rates over

299 (85.7%)*,**,***

210 (60.2%)*,**
12 weeks of treatment across bodyweight categories for patients

90 (25.8%)*,**
treated with PBO, ETN or IXE Q2W. *P ≤ 0.05, Q2W vs. PBO,

[82.0, 89.3]

[55.0, 65.3]

[21.2, 30.4]
≥100 kg
CMH test stratified by study. **P ≤ 0.001, Q2W vs. PBO, CMH
test stratified by study. †P ≤ 0.05, Q2W vs. ETN, CMH test strati-

349
fied by study. ††P ≤ 0.05, Q2W vs. ETN, CMH test stratified by

380 (89.4%)*,**

300 (70.6%)*,**

166 (39.1%)*,**
study. Comparisons with ETN included patients enrolled in

80 to <100 kg
UNCOVER-2 and UNCOVER-3 only. (b) PASI 75, PASI 90 and

[86.5, 92.3]

[66.3, 74.9]

[34.4, 43.7]
PASI 100 response rates over 12 weeks of treatment across body-
weight categories for patients treated with IXE Q2W or IXE Q4W.

425
*P ≤ 0.05, Q4W vs. PBO, CMH test stratified by study.
**P ≤ 0.001, Q4W vs. PBO, CMH test stratified by study.

358 (90.9%)*,**,***
†
P ≤ 0.05, Q4W vs. ETN, CMH test stratified by study. ††P ≤ 0.05,

184 (46.7%)*,**
307 [77.9%)*,**
[88.0, 93.7]

[73.8, 82.0]

[41.8, 51.6]
Q4W vs. ETN, CMH test stratified by study. Comparisons with ETN

N = 1168
IXE Q2W

<80 kg
included patients enrolled in UNCOVER-2 and UNCOVER-3 only.
#
P ≤ 0.05, Q4W vs. Q2W, CMH test stratified by study.

394
##
P ≤ 0.001, Q4W vs. Q2W, CMH test stratified by study. ETN,

273 (74.2%)*,**

194 (52.7%)*,**
etanercept; IXE Q4W, 80-mg ixekizumab every 4 weeks; IXE Q2W,

81 (22.0%)*,**
80-mg ixekizumab every 2 weeks; PASI, Psoriasis Area and Sever-

[69.7, 78.7]

[47.6, 57.8]

[17.8, 26.2]
≥100 kg
ity Index; PBO, placebo.

368
374 (85.6%)*,**

286 (65.4%)*,**

150 (34.3%)*,**
80 to <100 kg

[82.3, 88.9]

[61.0, 69.9]

[29.9, 38.8]
similar frequency for each treatment group (range: 1.3–2.6%).

437
Four SAEs were reported in more than one patient per body-
weight category: cellulitis (<80 kg PBO, n = 1; ≥100 kg ETN,

303 (85.6%)*,**

257 (72.6%)*,**

155 (43.8%)*,**
n = 1; <80 kg IXE Q4W, n = 2, P < 0.05 vs. PBO; ≥100 kg IXE

[81.9, 89.3]

[68.0, 77.2]

[38.6, 49.0]
Q2W, n = 1), appendicitis (80 to <100 kg IXE Q2W, n = 2),
N = 1159
IXE Q4W

<80 kg

depression (≥100 kg IXE Q2W, n = 2) and neoplasms (<80 kg

354

PBO, n = 1; <80 kg ETN, n = 1; ≥100 kg ETN, n = 2; <80 kg

IXE Q4W, n = 1).
93 (37.1%)*

29 (11.6%)*
[31.1, 43.0]

[7.6, 15.5]
9 (3.6%)*
[1.3, 5.9]
≥100 kg

**P ≤ 0.001 vs. ETN using CMH test stratified by study; UNCOVER-2 and UNCOVER-3 only.
The most frequently reported infections, nasopharyngitis
251

and upper respiratory tract infections, occurred at similar

rates across bodyweight categories within each treatment
80 to <100 kg

123 (48.4%)*

64 (25.2%)*
[42.3, 54.6]

[19.9, 30.5]

group (Table 4). The incidence of candidal infections was

15 (5.9%)*
[3.0, 8.8]

generally consistent across bodyweight categories within each

Table 2 PASI response rates at week 12 by bodyweight category

254

treatment group (range: 0.4–1.4%; Table 4). Oral candidiasis

***P ≤ 0.001, IXE Q4W vs. IXE Q2W using CMH test stratified by study.

was the most frequently reported candidal infection (n = 11

137 (58.5%)*

72 (30.8%)*
[52.2, 64.9]

[24.9, 36.7]
23 (9.8%)*

total cases) with a statistically higher incidence [1.4%

[6.0, 13.6]
N = 739

<80 kg

(n = 6)] occurring in the 80 to <100 kg IXE Q2W group

ETN

234

[vs. ETN (0.4%, n = 1), P < 0.05]. The five remaining cases
*P ≤ 0.05 vs. PBO using CMH test stratified by study.

of oral candidiasis were experienced by one patient in each

[1.0, 5.4]
≥100 kg

8 (3.2%)

of the following bodyweight categories: <80 kg ETN; 80 to

251

<100 kg IXE Q4W, ≥100 IXE Q4W, <80 kg IXE Q2W and
80 to <100 kg

≥100 kg IXE Q2W. Vulvovaginal candidiasis (<80 kg PBO,

16 (5.7%)

n = 2 and 80 to <100 kg IXE Q4W, n = 2) and skin can-

[3.0, 8.4]

[0.2, 3.3]
5 (1.8%)

1 (0.4%)
[0, 1.1]

didiasis (≥100 kg IXE Q2W, n = 2) were the only other

280

Physician’s Global Assessment.

types of candidal infections experienced by more than one

11 (4.3%)

patient per bodyweight category.

[1.8, 6.7]
4 (1.6%)
N = 789

<80 kg

[0, 3.1]
PBO

Across bodyweight categories, the incidence of treatment-

258

emergent (TE) Grade 3 or worse neutropenia (defined as neu-

PASI 100, n (%)

trophils <1000 to 500/mm3) was similar across all four treatment

PASI 75, n (%)

PASI 90, n (%)

groups. Only one patient (≥100 kg IXE Q4W group) experi-

[95% CI]

[95% CI]

[95% CI]

enced TE Grade 4 or worse neutropenia (defined as neutrophils

<500/mm3).
N

JEADV 2017, 31, 1196–1207 © 2017 European Academy of Dermatology and Venereology
1204 Reich et al.

Discussion Across bodyweight categories, patients receiving IXE Q2W

To gain a better understanding of the impact of bodyweight on
the efficacy and safety of ixekizumab in the treatment of moder-
ate-to-severe psoriasis, we evaluated data from an integrated
database of three Phase 3 placebo-controlled ixekizumab trials.
Our findings suggest that ixekizumab is efficacious in the treat-
ment of moderate-to-severe plaque psoriasis regardless of body-
weight. The safety profile of ixekizumab was also similar across
bodyweight categories, and no safety signals were identified
specific to any of the bodyweight categories.
Consistent with the primary Phase 3 ixekizumab trials,5,6
across bodyweight categories, patients in the ixekizumab
groups experienced rapid onset of efficacy (PASI 75 as early
as Week 1) and roughly half experienced PASI 75 by Week
4. At Week 12, up to 78% of patients had achieved PASI
90 and up to 47% of patients had achieved complete resolu-
tion of psoriasis (as measured by PASI 100 and sPGA 0).
There were no meaningful differences in the PASI 75
response rates of patients across bodyweight categories in
the IXE Q2W groups, whereas there was a numerical trend
towards decreasing PASI 75 response rates with higher body-
weight in the IXE Q4W groups. Additionally, there was a
numerical trend towards higher bodyweight having an
impact on PASI 90 and PASI 100. Overall, both ixekizumab
treatment groups demonstrated higher efficacy across all
bodyweight categories relative to PBO and ETN.
had higher PASI response rates than those receiving IXE Q4W.
This effect is also consistent with the primary result of
UNCOVER-1, UNCOVER-2 and UNCOVER-3 and is support-
ive of the label dose indication that more frequent dosing pro-
vides higher benefit to the patient with psoriasis.5,6
The short-term safety profile across bodyweight categories
in the ixekizumab treatment groups was generally compara-
ble with the ETN group, with the exception of candidiasis,
and was also consistent with previous studies of ixek-
izumab.5,6 The higher frequency of Candida infections
among patients in the ixekizumab treatment groups than
those in the PBO and ETN groups, regardless of body-
weight, is consistent with the role of IL-17A in the mucocu-
taneous defence against fungal infections.7 These events were
treatable and did not lead to discontinuation of the study
drug. Generally and similar to the ETN group, there was a
higher overall incidence of TEAEs and infections in the
ixekizumab treatment groups, regardless of bodyweight. The
higher rates of TEAEs were primarily driven by injection-site
reactions, which were observed at similar rates with ETN
and were primarily mild or moderate in severity.
The main limitation reported here is that the data are lim-
ited to short-term treatment (12-week duration). To fully
assess the impact of bodyweight, analyses of longer term
treatment are required. Although this study analysed the data

n = 307 (27.2%) n = 300 (26.6%) n = 210 (18.6%)

100
PASI 90 n = 817
90
80 PASI 75 n = 220
70
60
50
Percent Improvement in PASI

n = 51 n = 80 n = 89
40 (4.5%) (7.1%) (7.9%)
30
20
10 n = 90
0
-10
-20
-30
n = 23 n = 26 n = 41
-40
(2.0%) (2.3%) (3.6%)
-50
-60
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200

Weight (kg)

Figure 4 Scatterplot of PASI percent improvement at Week 12 by baseline bodyweight for the IXE Q2W treatment group (observed data;
integrated from UNCOVER-1, UNCOVER-2 and UNCOVER-3 studies; N = 1127). IXE Q2W, 80-mg ixekizumab every 2 weeks; PASI 75,
75% improvement from baseline on the Psoriasis Area and Severity Index; PASI 90, 90% improvement from baseline on the Psoriasis
Area and Severity Index.

JEADV 2017, 31, 1196–1207 © 2017 European Academy of Dermatology and Venereology
Effect of bodyweight on ixekizumab treatment 1205

Table 3 Efficacy outcomes by body mass index categories

PBO ETN IXE Q4W IXE Q2W

N = 789 N = 739 N = 1159 N = 1168
PASI 75
Underweight 1 (10.0%) 3 (75.0%) 6 (85.7%)* 5 (71.4%)*
Normal 9 (5.5%) 85 (54.8%)* 203 (88.6%)*,** 222 (90.6%)*,**
Overweight 9 (3.5%) 128 (57.1%)* 332 (85.6%)*,** 367 (91.8%)*,**
,
Obese 11 (4.1%) 112 (42.1%)* 323 (78.0%)* ** 345 (86.5%)*,**
Extreme obese 5 (6.0%) 25 (27.8%)* 84 (71.8%)*,** 97 (83.6%)*,**
PASI 90
Underweight 0 1 (25.0%) 6 (85.7%)* 5 (71.4%)*
Normal 3 (1.8%) 42 (27.1%)* 176 (76.9%)*,** 187 (76.3%)*,**
Overweight 3 (1.2%) 66 (29.5%)* 261 (67.3%)*,** 297 (74.3%)*,**
,
Obese 3 (1.1%) 48 (18.0%)* 237 (57.2%)* ** 258 (64.7%)*,**
,
Extreme obese 0 8 (8.9%)* 55 (47.0%)* ** 69 (59.5%)*,**
PASI 100
Underweight 0 1 (25.0%) 3 (42.9%)* 4 (57.1%)*
Normal 0 14 (9.0%)* 112 (48.9%)*,** 111 (45.3%)*,**
Overweight 1 (0.4%) 16 (7.1%)* 138 (35.6%)*,** 172 (43.0%)*,**
,
Obese 0 14 (5.3%)* 111 (26.8%)* ** 123 (30.8%)*,**
,
Extreme obese 0 2 (2.2%)* 21 (17.9%)* ** 29 (25.0%)*,**
sPGA 0,1
Underweight 1 (10.0%) 2 (50.0%) 5 (71.4%)* 5 (71.4%)*
Normal 8 (4.9%) 70 (45.2%)* 192 (83.8%)*,** 211 (86.1%)*,**
Overweight 11 (4.2%) 114 (50.9%)* 309 (79.6%)*,** 343 (85.8%)*,**
Obese 9 (3.3%) 89 (33.5%)* 296 (71.5%)*,** 320 (80.2%)*,**
,
Extreme obese 2 (2.4%) 13 (14.4%) 69 (59.0%)* ** 76 (65.5%)*,**
sPGA 0
Underweight 0 1 (25.0%) 3 (42.9%)* 4 (57.1%)*
Normal 0 18 (11.6%)* 114 (49.8%)*,** 115 (46.9%)*,**
Overweight 1 (0.4%) 18 (8.0%)* 143 (36.9%)*,** 183 (45.8%)*,**
Obese 0 15 (5.6%)* 117 (28.3%)*,** 129 (32.3%)*,**
,
Extreme obese 0 2 (2.2%) 21 (17.9%)* ** 30 (25.9%)*,**

*P ≤ 0.05 vs. PBO, CMH test stratified by study. Comparisons with ETN included patients enrolled in UNCOVER-2 and UNCOVER-3 only.
**P ≤ 0.05 vs. ETN, CMH test stratified by study. Comparisons with ETN included patients enrolled in UNCOVER-2 and UNCOVER-3 only.
BMI categories were underweight <18.5 kg/m2; normal ≥18.5 to <25 kg/m2; overweight ≥25 to <30 kg/m2; obese ≥30 to <40 kg/m2; and extreme obese
≥40 kg/m2.
BMI, body mass index; ETN, etanercept; IXE Q4W, ixekizumab dosing every 4 weeks; IXE Q2W, ixekizumab dosing every 2 weeks; PASI, Psoriasis Area
and Severity Index; PBO, placebo; sPGA, static Physician’s Global Assessment.

by three baseline bodyweight categories, patients were not Conclusions

randomised according to baseline bodyweight in two of the
three Phase 3 studies. Additionally, based on a logistic regres-
sion model, testing the effects of treatment, bodyweight and
treatment-by-bodyweight interaction, no significant treatment-
by-bodyweight interaction was observed, but a highly signifi-
cant treatment effect was found for all sPGA and PASI
responses, while the bodyweight effect was not certain for
some responses. Therefore, the statistical comparisons
between bodyweight categories were not conducted as the
efficacy of ixekizumab over PBO and ETN did not vary
across weight categories.
Across all bodyweight categories, patients treated with ixek-
izumab had significantly higher PASI and sPGA response
rates than patients treated with ETN or PBO and these sig-
nificant improvements were observed as early as Week 1.
Additionally, patients treated with IXE Q2W had higher
PASI response across all the PASI thresholds (PASI 75, 90
and 100) than patients treated with IXE Q4W regardless of
bodyweight. The short-term safety profile of ixekizumab was
comparable to that of ETN and was consistent with previous
studies of ixekizumab with no safety signals specific to any
bodyweight category.

JEADV 2017, 31, 1196–1207 © 2017 European Academy of Dermatology and Venereology
 1206

Table 4 Overview of safety

PBO ETN IXE Q4W IXE Q2W

JEADV 2017, 31, 1196–1207

N = 789 N = 739 N = 1159 N = 1168
<80 kg 80 to <100 kg ≥100 kg <80 kg 80 to <100 kg ≥100 kg <80 kg 80 to <100 kg ≥100 kg <80 kg 80 to <100 kg ≥100 kg
N 258 280 251 234 254 251 354 437 368 393 425 349
TEAEs 126 (49%) 124 (44%) 119 (47%) 129 (55%)* 133 (52%)* 137 (55%) 226 (64%)* 242 (55%)* 214 (58%)* 235 (60%)* 247 (58%)* 199 (57%)*
TEAEs‡
Nasopharyngitis 25 (10%) 23 (8%) 21 (8%) 20 (9%) 15 (6%) 20 (8%) 34 (10%) 38 (9%) 32 (9%) 44 (11%) 36 (9%) 31 (9%)
URT infection 13 (5%) 7 (3%) 8 (3%) 11 (5%) 7 (3%) 16 (6%) 9 (3%) 16 (4%) 20 (5%) 14 (4%) 19 (5%) 18 (5%)
Injection-site 7 (3%) 2 (<1%) 0 30 (13%)* 28 (11%)* 22 (9%)* 37 (11%)* 26 (6%)* 25 (7%)* 40 (10%)* 43 (10%)* 34 (10%)*
reaction
Discontinued due 2 (<1%) 3 (1%) 4 (2%) 3 (1%) 1 (<1%) 5 (2%) 10 (3%) 11 (3%) 3 (<1%) 6 (2%) 12 (3%) 7 (2%)
to AE
Deaths 0 0 0 0 0 0 0 0 0 0 0 0
SAEs 4 (2%) 4 (1%) 4 (2%) 4 (2%) 4 (2%) 6 (2%) 8 (2%) 11 (3%) 7 (2%) 5 (1%) 6 (1%) 9 (3%)
All Infections 68 (26%) 53 (19%) 60 (24%) 50 (21%) 45 (18%) 64 (26%) 103 (29%) 115 (26%)*,** 100 (27%)** 116 (30%) 111 (26%)* 88 (25%)
Tonsillitis 1 (<1%) 0 1 (<1%) 0 0 0 6 (2%) 2 (<1%) 0 4 (1%) 0 0
Influenza 0 0 0 3 (1%) 3 (1%) 0 1 (<1%) 2 (<1%) 7 (2%)* 1 (<1%) 4 (<1%) 3 (<1%)
Candidiasis† 2 (<1%) 0 1 (<1%) 1 (<1%) 1 (<1%) 2 (<1%) 2 (<1%) 3 (<1%) 0 4 (1%) 6 (1%) 3 (<1%)
Neutropenia
TE Grade 1 or 6 (2%) 9 (3%) 10 (4%) 37 (16%)* 39 (15%)* 17 (7%) 37 (11%)* 34 (8%)*,** 22 (6%) 46 (12%)* 35 (8%)*,** 18 (5%)
worse
TE Grade 2 or 1 (<1%) 1 (<1%) 1 (<1%) 8 (3%) 11 (4%)* 9 (4%) 9 (3%) 8 (2%) 6 (2%) 15 (4%)* 6 (1%) 6 (2%)
worse
TE Grade 3 or 0 0 1 (<1%) 0 3 (1%) 1 (<1%) 0 0 1 (<1%) 0 1 (<1%) 1 (<1%)
worse
TE Grade 4 0 0 0 0 0 0 0 0 1 (<1%) 0 0 0

*P ≤ 0.05 vs. PBO, CMH test stratified by study. Comparisons with ETN included patients enrolled in UNCOVER-2 and UNCOVER-3 only.
**P ≤ 0.05 vs. ETN, CMH test stratified by study. Comparisons with ETN included patients enrolled in UNCOVER-2 and UNCOVER-3 only.
†
Five patients in the IXE Q2W group in the 80 to <100 kg bodyweight category experienced oral candidiasis in UNCOVER-2 and UNCOVER-3. One additional from UNCOVER-1 also experienced oral
candidiasis.
‡
≥5% of patients in each ixekizumab-treated bodyweight category.
AE, adverse event; ETN, etanercept; IXE Q4W, ixekizumab dosing every 4 weeks; IXE Q2W, ixekizumab dosing every 2 weeks; PBO, placebo; SAEs, serious adverse events; TE, treatment-emergent,
URT, upper respiratory tract.
Reich et al.

© 2017 European Academy of Dermatology and Venereology

Effect of bodyweight on ixekizumab treatment
Acknowledgements
The authors would like to acknowledge Janelle Erickson of Eli
Lilly and Company (Indianapolis, IN) for her thorough review
and input on the manuscript and would also like to acknowledge
Kelly Guerrettaz, inVentiv Health Clinical (Princeton, NJ), for
her assistance with manuscript writing.
References
1 Christophers E. Psoriasis—epidemiology and clinical spectrum. Clin Exp
Dermatol 2001; 26: 314–320.
2 Armstrong AW, Harskamp CT, Armstrong EJ. The association between
psoriasis and obesity: a systematic review and meta-analysis of observa-
tional studies. Nutr Diabetes 2012; 2: e54.
JEADV 2017, 31, 1196–1207
1207
3 Puig L. Obesity and psoriasis: body weight and body mass index influence
the response to biological treatment. J Eur Acad Dermatol Venereol 2011;
25: 1007–1011.
4 Liu L, Lu J, Allan BW et al. Generation and characterization of ixek-
izumab, a humanized monoclonal antibody that neutralizes interleukin-
17A. J Inflamm Res 2016; 9: 39–50.
5 Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab
in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375: 345–
356.
6 Griffiths CE, Reich K, Lebwohl M et al. Comparison of ixekizumab with
etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and
UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015;
386: 541–551.
7 Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells.
N Engl J Med 2009; 361: 888–898.
© 2017 European Academy of Dermatology and Venereology